In today’s recent session, 0.46 million shares of the Sangamo Therapeutics Inc (NASDAQ:SGMO) have been traded, and its beta is 1.48. Most recently the company’s share price was $1.15, and it changed around $0.0 or 0.43% from the last close, which brings the market valuation of the company to $240.98M. SGMO at last check was trading at a discount to its 52-week high of $3.18, offering almost -176.52% off that amount. The share price’s 52-week low was $0.30, which indicates that the recent value has risen by an impressive 73.91% since then. We note from Sangamo Therapeutics Inc’s average daily trading volume that its 10-day average is 4.22 million shares, with the 3-month average coming to 7.38 million.
Sangamo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.88. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended SGMO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Sangamo Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO has been showing a green trend so far today with a performance of 0.43% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4000 on recent trading dayincreased the stock’s daily price by 17.86%. The company’s shares are currently up 13.24% year-to-date, but still down -1.28% over the last five days. On the other hand, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -4.94% down in the 30-day period. We can see from the shorts that 22.45 million shares have been sold at a short interest cover period of 1.97 day(s).
The consensus price target as assigned by Wall Street analysts is $2.5, which translates to bulls needing to increase their stock price by 54.0% from its current value. Analyst projections state that SGMO is forecast to be at a low of $2 and a high of $3.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
The year-over-year growth rate is expected to be -64.54%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 11.7M in revenue for the current quarter. 3 analysts expect Sangamo Therapeutics Inc to make 30.67M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.04M and 481k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 472.97%. Forecasts for the next quarter put sales growth at 6,275.61%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.96%. Sangamo Therapeutics Inc earnings are expected to increase by 68.41% in 2025, but the outlook is positive 43.70% per year for the next five years.
SGMO Dividends
Sangamo Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.38% of Sangamo Therapeutics Inc shares, and 25.27% of them are in the hands of institutional investors. The stock currently has a share float of 25.89%. Sangamo Therapeutics Inc stock is held by 126.0 institutions, with WASATCH ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 11.1403% of the shares, which is about 20.09 million shares worth $7.2 million.
ARMISTICE CAPITAL, LLC, with 7.7963% or 14.06 million shares worth $5.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Wasatch Microcap Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 10.97 shares worth $12.46 million, making up 5.26% of all outstanding shares. On the other hand, Wasatch Microcap Fund held roughly 5.65 shares worth around $6.41 million, which represents about 2.71% of the total shares outstanding.
